244 GM-CSF induced activation of T-lymphocytes and macrophages

• Published in: European journal of cancer (1990) Vol. 31; p. S53
• Main Authors: Liberati, A.M., Adiuto, D., Cecchini, M., Messina, S., Brozzi, F., Mancini, S., Di Clemente, F., Cinieri, S., Trottini, M., Schippa, M.
• Format: Journal Article
• Language: English
• Published: Elsevier Ltd 01-11-1995
• ISSN: 0959-8049; 1879-0852
• DOI: 10.1016/0959-8049(95)95502-W

The effect of GM-CSF infused after 7
g/m
2 cyclophosphamide (CTX) and 800
mg/m
2 carboplatinum (CBDCA) was evaluated in 16 (LGNHL, MM, HD) patients. Serum concentrations of soluble CD8 (sCD8) and soluble IL-2 receptor (sIL-2R) as well as circulating levels of IL-2, IFN-γ, neopterin, IL-1α, ILl-β, TNF-α and IL-6 were determined on day 0 and days +4, +10 and +16 post-GM-CSF and intracellular IL-2, IFN-γ, IL-1α, IL1-β, TNF-α and IL-6 on days 0 and +16. sIL-2 R rose from day +4 to day + 16 and reached twice basal values at 10 and 16 days after both CTX (2266
±
904, 2292
±
873 vs 1189
±
608) and CBDCA (2225
±
965, 2313
±
1055 vs 1151
±
518). Neopterin also rose and was maximum on day +16 (1.7 post-CTX, 1.6 post-CBDCA vs basal). Serum IL-1α concentrations varied little after CTX, but increased two-fold over basal values after CBDCA (39.3
±
34.6 vs 15.8
±
40.5). Serum IL-1β increased 1.3 on the 16th post-GM-CSF day after CTX and 1.8 after CBDCA. Serum TNF-α rose to 1.8 basal values on day +10 and to 3.5 on day +16 following CBDCA, but not after CTX. Changes in the other serum and intracellular indices studied were negligible. These results suggest that GM-CSF activates T-Iymphocytes and macrophages, but that their activation partially depends on the therapy that precedes administration of the growth factor.